May 28, 2016
Edinburgh, UK

Solid at the 8th Annual ECRD Meeting

In May, Solid had the honor of participating in the 8th European Conference on Rare Diseases & Orphan Products in Edinburgh, which is organized bi-annually by the European Organisation for Rare Diseases (EURODIS) and DIA Europe, Middle East & Africa.

ECRD is one of the foremost meetings of the rare disease community, offering those impacted by rare diseases and those committed to solving them with the opportunity to share ideas, concerns and progress.

During the meeting, Carl Morris, Ph.D., Solid’s vice president of Research & Development, showcased why Solid fits naturally into the conference’s theme of “Game Changers in Rare Disease.”  During a panel discussion called “Launch Platforms,” Dr. Morris discussed Solid’s unique business model that focuses solely on solving Duchenne muscular dystrophy, regardless of technology or modality. Dr. Morris also discussed our novel strategies to partner with the community and develop tested collaborations. 

“It is through working together, sharing our learnings and progress, and listening to the experiences of others that we will be successful in our goal to address all facets of Duchenne muscular dystrophy and improve the quality of life for those impacted by the disease,” said Dr. Morris.

To learn more about our approach to therapy and assistive device development,

Click Here

Related news


Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of President
Gilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities


We’re pleased to share with you that the FDA has lifted the clinical hold on IGNITE DMD.


- Activities to Resume Enrollment in IGNITE DMD Phase I/II Clinical Trial are Underway

- Conference Call Scheduled for Today at 8:30 A.M. ET


- Data Reinforce Potential of SGT-001 as an Important Treatment Candidate for DMD -

- Company Continues to Advance Gene Therapy Portfolio -

Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial

- Full Clinical Hold Letter from the FDA Received; Company to Respond in the Coming Weeks -

- Manufacturing-related Partial Clinical Hold on the High Dose of SGT-001 Resolved -


Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year ended December 31, 2017 and provided a corporate update.


Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.


Solid Biosciences is proud to join the global rare disease community again this year to observe Rare Disease Day


Phase I/II adaptive clinical trial to evaluate safety and efficacy in ambulatory and non-ambulatory children and adolescents.


More information about Solid?

Please subscribe to receive our latest news